AstraZeneca (AZN) stock price, revenue and financials

View Company

+1.74 (+4.64%)

$94.9 B

AZN Mkt cap, 15-Oct-2018

£22.5 B

AstraZeneca Revenue FY, 2017

AstraZeneca Gross profit (FY, 2017)18.1 B

AstraZeneca Gross profit margin (FY, 2017), %80.8%

AstraZeneca Net income (FY, 2017)2.9 B

AstraZeneca EBITDA (FY, 2017)6.7 B

AstraZeneca EBIT (FY, 2017)3.7 B

AstraZeneca Cash, 31-Dec-20173.3 B

AstraZeneca EV93.9 B

AstraZeneca Revenue

AstraZeneca revenue was £22.46 b in FY, 2017

Embed Graph

AstraZeneca Revenue Breakdown

Business Segment

Embed Graph

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

Annual

GBP	FY, 1996	FY, 1997	FY, 1998	FY, 1999	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2008	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	5.4b	5.2b	5.5b	11.4b	12.1b	11.4b	11.1b	10.5b	11.5b	14.0b	13.5b	14.8b	19.8b	16.9b	19.6b	19.1b	23.0b	22.5b
Revenue growth, %															1%	(9%)	(10%)
Cost of goods sold	2.2b	2.0b	2.2b	3.7b	3.7b	3.1b	2.8b	2.5b	2.8b	3.1b	2.7b	3.2b	4.1b	3.5b	4.3b	3.6b	4.1b	4.3b
Gross profit	3.1b	3.2b	3.4b	7.6b	8.4b	8.3b	8.3b	8.0b	8.7b	10.8b	10.8b	11.6b	15.7b	13.4b	15.3b	15.5b	18.9b	18.1b
Gross profit Margin, %	58%	62%	61%	67%	70%	73%	75%	76%	76%	78%	80%	78%	79%	80%	78%	81%	82%	81%
Operating expense total	2.2b	2.2b	2.4b	5.9b	5.8b	5.6b	5.8b	5.7b	6.2b	7.0b	6.6b	7.6b	10.0b	11.0b	13.7b	12.4b	14.0b	14.5b
Depreciation and amortization														4.6b	3.3b	2.9b
EBITDA											4.9b	4.9b	7.0b	3.0b	4.0b			6.7b
EBITDA margin, %											36%	33%	35%	18%	20%			30%
EBIT	942.0m	1.0b	982.0m	1.7b	2.7b	2.7b	2.5b	2.3b	2.6b	3.8b	4.2b	4.1b	5.7b	2.4b	1.6b	3.2b	4.9b	3.7b
EBIT margin, %	18%	19%	18%	15%	22%	24%	22%	22%	22%	27%	31%	27%	29%	14%	8%	17%	21%	16%
Pre tax profit	975.0m	1.1b	1.0b	1.2b	2.6b	2.8b	2.5b	2.3b	2.7b	3.9b	4.4b	4.0b	5.4b	2.1b	921.4m	2.4b	3.6b	2.2b
Income tax expense	(320.0m)	(345.0m)	(330.0m)	(502.0m)	(869.0m)	(762.0m)	(735.0m)	(639.0m)	(671.0m)	(1.1b)	(1.3b)	(1.2b)	(1.6b)	(457.7m)	(8.1m)	(188.2m)	(146.0m)	641.0m
Net Income	655.0m	736.0m	715.0m	704.0m	1.7b	2.1b	1.8b	1.7b	2.1b	2.8b	3.1b	2.8b	3.8b	1.7b	913.3m	2.2b	3.4b	2.9b

Source: Company Filings

Annual

GBP	FY, 1996	FY, 1997	FY, 1998	FY, 1999	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2008	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	259.0m	303.0m	206.0m	265.0m	683.0m	489.0m	453.0m	409.0m	565.0m	2.9b	3.6b	2.9b	2.7b	6.1b	4.7b	4.8b	5.0b	3.3b
Accounts Receivable	935.0m	969.0m	1.1b	1.8b	1.8b	1.7b	1.7b	1.8b	1.9b	2.2b	2.2b	2.7b	3.5b	3.6b	3.5b	3.6b	2.6b	2.8b
Inventories	681.0m	728.0m	798.0m	1.3b	1.4b	1.7b	1.6b	1.7b	1.6b	1.3b	1.2b	1.1b	1.0b	1.3b	1.4b	1.7b	2.3b	3.0b
Current Assets	3.0b	2.9b	2.7b	6.1b	7.0b	6.8b	7.6b	7.2b	7.7b	8.0b	8.7b	8.6b	10.0b	13.2b	12.2b	12.3b	13.0b	12.9b
PP&E	1.9b	2.1b	2.4b	3.8b	3.3b	3.8b	4.1b	4.3b	4.5b	4.9b	3.8b	4.2b	4.4b	3.8b	4.4b	7.6b	10.3b	7.6b
Goodwill														17.1b	24.1b	25.5b	30.4b
Total Assets	5.0b	5.0b	5.5b	12.2b	12.3b	12.5b	13.5b	13.2b	13.7b	14.5b	15.3b	24.1b	29.4b	36.8b	43.3b	46.5b	62.5b	63.4b
Accounts Payable	479.0m	529.0m	588.0m	997.0m	2.0b	1.7b	2.0b	1.7b	1.7b	1.8b	1.8b	1.8b	2.4b	1.6b	2.6b	2.7b	10.5b	11.6b
Current Liabilities	1.9b	1.9b	2.1b	4.3b	4.6b	4.5b	5.1b	4.3b	4.2b	4.0b	4.8b	7.6b	8.4b	10.6b	12.8b	11.5b	15.3b	16.4b
Non-Current Liabilities	1.1b	987.0m	893.0m	1.5b	1.3b	1.2b	1.4b	1.5b	1.8b	2.6b	2.6b	9.0b	11.0b	10.9b	16.0b	20.7b	32.4b	32.0b
Total Debt				103.0m	76.0m	135.0m	126.0m	85.0m	75.0m	52.0m	69.0m	2.1b	102.3m	1.2b	144.9m		2.3b	2.2b
Total Liabilities	3.0b	2.8b	3.0b	5.9b	6.0b	5.7b	6.5b	5.8b	6.0b	6.6b	7.5b	16.6b	19.4b	21.5b	28.8b	32.2b	47.7b	48.4b
Additional Paid-in Capital	237.0m	237.0m	238.0m	274.0m	296.0m	302.0m	268.0m	236.0m	220.0m	230.0m	196.0m	183.0m	227.1m	207.1m	233.7m	244.7m	316.0m	317.0m
Retained Earnings	311.0m	365.0m	315.0m	(61.0m)	(245.0m)	1.2b	1.0b	942.0m	1.2b	1.8b	2.0b	1.5b	2.1b	1.7b	(1.7b)	(511.2m)	3.3b	2.7b
Total Equity	2.0b	2.2b	2.5b	6.4b	6.4b	6.8b	7.0b	7.4b	7.7b	7.9b	7.8b	7.4b	10.0b	15.3b	14.5b	14.3b	14.9b	15.0b
Debt to Equity Ratio				0 x	0 x	0 x	0 x	0 x	0 x	0 x	0 x	0.3 x	0 x	0.1 x	0 x		0.2 x	0.2 x
Debt to Assets Ratio				0 x	0 x	0 x	0 x	0 x	0 x	0 x	0 x	0.1 x	0 x	0 x	0 x		0 x	0 x
Financial Leverage	2.5 x	2.3 x	2.2 x	1.9 x	1.9 x	1.8 x	1.9 x	1.8 x	1.8 x	1.8 x	2 x	3.2 x	2.9 x	2.4 x	3 x	3.2 x	4.2 x	4.2 x

Annual

GBP	FY, 1996	FY, 1997	FY, 1998	FY, 1999	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2008	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	655.0m	736.0m	715.0m	704.0m	1.7b	2.1b	1.8b	1.7b	2.1b	2.8b	3.1b	2.8b	3.8b	1.7b	913.3m	2.2b	3.4b	2.9b
Cash From Operating Activities	1.1b	1.2b	1.2b	1.9b	2.8b	2.6b	3.5b	2.4b	3.2b	3.9b	3.9b	3.8b	5.5b	4.9b	5.2b	4.0b	4.1b	3.6b
Dividends Paid	332.0m	365.0m	399.0m	764.0m	1.9b	850.0m	753.0m	754.0m	833.0m	976.0m	1.1b	1.3b	1.7b		2.6b	2.7b
Cash From Financing Activities	(39.0m)	(32.0m)	(96.0m)	(112.0m)	(267.0m)	(665.0m)	(794.0m)	(811.0m)	(740.0m)	(2.7b)	(2.7b)	3.0b	(4.0b)	(2.0b)	(2.0b)	3.4b	(1.3b)	(2.9b)
Net Change in Cash	101.0m	73.0m	112.0m	172.0m	428.0m	275.0m	14.0m	2.0m	165.0m	576.0m	1.1b	665.0m	(951.2m)	962.7m	(2.0b)	(28.7m)	(1.1b)	(1.7b)
Income Taxes Paid														(457.7m)	(8.1m)	(179.7m)	(113.1m)

GBP	Y, 2017
EV/EBITDA	14 x
EV/EBIT	25.5 x
EV/CFO	26.2 x
Revenue/Employee	367.7k
Debt/Equity	0.2 x
Financial Leverage	4.2 x

Download Excel

Report incorrect company information

	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Healthcare Workers			2.60 k	3 k
Countries	100	100	100	100
Drugs Approved by FDA			1
Health Facilities Activated			250	403
NME in Late-stage Development	7	13	15	12
Phase I Trials Products	33	24	44	41
Phase II Trials Products	27	11	33	36
Phase III Trials Products	19	11	35	27
Projects in R&D Pipeline	99	133	146	132
Young Health Programme Members			1.40 m	1.60 m